Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.83 Consensus Price Target from Brokerages

Blueprint Medicines Co. (NASDAQ:BPMC) has earned an average rating of “Moderate Buy” from the twenty research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $123.83.

A number of research analysts recently commented on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Saturday, February 22nd. Wedbush reaffirmed an “outperform” rating and issued a $128.00 target price (up from $124.00) on shares of Blueprint Medicines in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, Stephens reiterated an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 1,819 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the sale, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,577 shares of company stock worth $4,768,439 over the last ninety days. 4.21% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP acquired a new position in shares of Blueprint Medicines during the third quarter worth $32,000. R Squared Ltd acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $51,000. Covestor Ltd lifted its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $65,000. Finally, Thematics Asset Management acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $72,000.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $91.40 on Monday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market capitalization of $5.84 billion, a price-to-earnings ratio of -84.63 and a beta of 0.61. The company’s 50-day moving average is $99.38 and its two-hundred day moving average is $94.40. Blueprint Medicines has a 1-year low of $80.68 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Analysts forecast that Blueprint Medicines will post -1.28 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.